Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

ABSTRACT:

SUBMITTER: Kiladjian JJ 

PROVIDER: S-EPMC8938906 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature